160 related articles for article (PubMed ID: 33811034)
1. Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial.
So H; Cheng IT; Lau SL; Chow E; Lam T; Hung VW; Li EK; Griffith JF; Lee VW; Shi L; Huang J; Kwok KY; Yim CW; Li TK; Lo V; Lee J; Lee JJ; Qin L; Tam LS
Ann Rheum Dis; 2021 Aug; 80(8):981-988. PubMed ID: 33811034
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT.
Iwamoto N; Sato S; Sumiyoshi R; Chiba K; Miyamoto N; Arinaga K; Kobayashi M; Yamamoto H; Osaki M; Kawakami A
Trials; 2019 Aug; 20(1):494. PubMed ID: 31409388
[TBL] [Abstract][Full Text] [Related]
3. Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT).
Shimizu T; Choi HJ; Heilmeier U; Tanaka M; Burghardt AJ; Gong J; Chanchek N; Link TM; Graf J; Imboden JB; Li X
Arthritis Res Ther; 2017 Oct; 19(1):222. PubMed ID: 28978352
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study.
Iwamoto N; Chiba K; Sato S; Shiraishi K; Watanabe K; Oki N; Okada A; Koga T; Kawashiri SY; Tamai M; Hosogaya N; Furuyama M; Kobayashi M; Saito K; Okubo N; Uetani M; Osaki M; Kawakami A
Arthritis Res Ther; 2022 Dec; 24(1):264. PubMed ID: 36476479
[TBL] [Abstract][Full Text] [Related]
5. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.
Takeuchi T; Tanaka Y; Ishiguro N; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D
Ann Rheum Dis; 2016 Jun; 75(6):983-90. PubMed ID: 26585988
[TBL] [Abstract][Full Text] [Related]
6. Effect of treat-to-target strategies on bone erosion progression in early rheumatoid arthritis: An HR-pQCT study.
Yue J; Griffith JF; Xu J; Xiao F; Shi L; Wang D; Wong PCH; Li EK; Li M; Li TK; Mak WY; Zhu TY; Hung VW; Qin L; Tam LS
Semin Arthritis Rheum; 2018 Dec; 48(3):374-383. PubMed ID: 29858113
[TBL] [Abstract][Full Text] [Related]
7. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.
Takeuchi T; Tanaka Y; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant HK; van der Heijde D
Ann Rheum Dis; 2019 Jul; 78(7):899-907. PubMed ID: 31036625
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.
Ishiguro N; Tanaka Y; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D; Takeuchi T
Rheumatology (Oxford); 2019 Jun; 58(6):997-1005. PubMed ID: 30602032
[TBL] [Abstract][Full Text] [Related]
9. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.
Cohen SB; Dore RK; Lane NE; Ory PA; Peterfy CG; Sharp JT; van der Heijde D; Zhou L; Tsuji W; Newmark R;
Arthritis Rheum; 2008 May; 58(5):1299-309. PubMed ID: 18438830
[TBL] [Abstract][Full Text] [Related]
10. Bone erosion in the 2nd metacarpophalangeal head: association with its bone mineral density by HR-pQCT in rheumatoid arthritis patients.
Figueiredo CP; Perez MO; Sales LP; Medeiros AC; Caparbo VF; Pereira RMR
BMC Musculoskelet Disord; 2021 Jan; 22(1):109. PubMed ID: 33494725
[TBL] [Abstract][Full Text] [Related]
11. Correlation of structural abnormalities of the wrist and metacarpophalangeal joints evaluated by high-resolution peripheral quantitative computed tomography, 3 Tesla magnetic resonance imaging and conventional radiographs in rheumatoid arthritis.
Lee CH; Srikhum W; Burghardt AJ; Virayavanich W; Imboden JB; Link TM; Li X
Int J Rheum Dis; 2015 Jul; 18(6):628-39. PubMed ID: 25293500
[TBL] [Abstract][Full Text] [Related]
12. Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction.
Tanaka Y; Soen S; Ishiguro N; Yamanaka H; Yoneda T; Tanaka S; Ohira T; Nitta T; Okubo N; Genant H; van der Heijde D; Takeuchi T
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32732353
[TBL] [Abstract][Full Text] [Related]
13. Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A High-Resolution Peripheral Quantitative Computed Tomography Study.
Yue J; Griffith JF; Xiao F; Shi L; Wang D; Shen J; Wong P; Li EK; Li M; Li TK; Zhu TY; Hung VW; Qin L; Tam LS
Arthritis Care Res (Hoboken); 2017 Aug; 69(8):1156-1163. PubMed ID: 27768831
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Cortical Interruptions in the Finger Joints of Patients With Rheumatoid Arthritis Using HR-pQCT, Radiography, and MRI.
Peters M; van Tubergen A; Scharmga A; Driessen A; van Rietbergen B; Loeffen D; Weijers R; Geusens P; van den Bergh J
J Bone Miner Res; 2018 Sep; 33(9):1676-1685. PubMed ID: 29750836
[TBL] [Abstract][Full Text] [Related]
15. Heterogenous bone response to biologic DMARD therapies in rheumatoid arthritis patients and their relationship to functional indices.
Brunet SC; Tse JJ; Kuczynski MT; Engelke K; Boyd SK; Barnabe C; Manske SL
Scand J Rheumatol; 2021 Nov; 50(6):417-426. PubMed ID: 33775211
[No Abstract] [Full Text] [Related]
16. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA).
Hetland ML; Ejbjerg B; Hørslev-Petersen K; Jacobsen S; Vestergaard A; Jurik AG; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Skjødt H; Pedersen JK; Majgaard O; Svendsen AJ; Ellingsen T; Lindegaard H; Christensen AF; Vallø J; Torfing T; Narvestad E; Thomsen HS; Ostergaard M;
Ann Rheum Dis; 2009 Mar; 68(3):384-90. PubMed ID: 18388160
[TBL] [Abstract][Full Text] [Related]
17. Bone changes in early inflammatory arthritis assessed with High-Resolution peripheral Quantitative Computed Tomography (HR-pQCT): A 12-month cohort study.
Brunet SC; Finzel S; Engelke K; Boyd SK; Barnabe C; Manske SL
Joint Bone Spine; 2021 Jan; 88(1):105065. PubMed ID: 32896669
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of high-resolution peripheral quantitative computed tomography and X-ray for classifying erosive rheumatoid arthritis.
Klose-Jensen R; Therkildsen J; Blavnsfeldt AG; Langdahl BL; Zejden A; Thygesen J; Keller KK; Hauge EM
Rheumatology (Oxford); 2022 Mar; 61(3):963-973. PubMed ID: 34015091
[TBL] [Abstract][Full Text] [Related]
19. Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study.
Tanaka Y; Takeuchi T; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant HK; van der Heijde D
J Rheumatol; 2021 Nov; 48(11):1663-1671. PubMed ID: 33858976
[TBL] [Abstract][Full Text] [Related]
20. Quantification of small joint space width, periarticular bone microstructure and erosions using high-resolution peripheral quantitative computed tomography in rheumatoid arthritis.
Barnabe C; Szabo E; Martin L; Boyd SK; Barr SG
Clin Exp Rheumatol; 2013; 31(2):243-50. PubMed ID: 23331665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
